Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF- ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.

In conclusion, our results suggest that bort selectively targets LSC in MLL rearrangements. Bort might be a prospective drug for AML patients bearing MLL rearrangements.
PMID: 33599085 [PubMed - as supplied by publisher]

Source: J Cell Mol Med - February 17, 2021 Category: Molecular Biology Authors: Zhou B, Qin Y, Zhou J, Ruan J, Xiong F, Dong J, Huang X, Yu Z, Gao S Tags: J Cell Mol Med Source Type: research